Advicenne SA logo

ADVIC - Advicenne SA News Story

€7.2 -0.0  -0.6%

Last Trade - 11:37am

Sector
Healthcare
Size
Small Cap
Market Cap £55.1m
Enterprise Value £41.1m
Revenue £1.50m
Position in Universe 558th / 852

BRIEF-Advicenne: 1st Patient Enrolled In US ARENA-2 Pivotal Phase III Clinical Trial Evaluating ADV7103 In dRTA

Thu 29th August, 2019 5:14pm
Aug 29 (Reuters) - ADVICENNE SA  ADVIC.PA :
    * ADVICENNE ANNOUNCES FIRST PATIENT ENROLLED IN US ARENA-2 PIVOTAL PHASE III CLINICAL TRIAL
EVALUATING ADV7103 IN DISTAL RENAL TUBULAR ACIDOSIS (DRTA)
    * ARENA-2 TRIAL IS EXPECTED TO INCLUDE APPROXIMATELY 40 PATIENTS
    * ADVICENNE HAS ALSO FILED AN APPLICATION FOR ORPHAN DRUG DESIGNATION (ODD) FOR ADV7103 IN
UNITED
STATES
    * ARENA-2: 8 STUDY CENTERS ARE ALREADY OPEN AND RESULTS ARE EXPECTED IN BEGINNING OF 2021
    * PRESENT STUDY WAS INITIATED FOLLOWING A EUROPEAN ARENA-1 CLINICAL TRIAL THAT DEMONSTRATED
POSITIVE RESULTS AFTER 24 MONTHS OF TREATMENT

Source text for Eikon:  ID:nBw9bHyKxa 
Further company coverage:  ADVIC.PA 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.